Stock Analiz

BGM Group Ltd. BGM

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$7.88Market cap $105M
Open the interactive analysis →

BGM Group Ltd. (BGM) is a healthcare company listed in the US with a market value of about $105M. In fiscal year 2025 it had revenue of $38M and net income of -$20M, a net margin of -52.6%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of -0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.

About BGM Group

BGM Group is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $50M in 2018 to $38M in 2025, a decline of about 4.0% a year. It was profitable in 5 of the last 8 years in our data. It spends 2% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.8
P/B0.3
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-3.8%
Shareholder yield0.0%
Intrinsic value vs. price−83%

Growth and quality

Revenue growth (1 yr)51.1%
Revenue growth (5 yrs, per year)-5.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-13.6%
ROIC (5-yr avg.)-0.2%
Profitable years (of last 10)5
Years paying a dividend2

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue$38M$25M$46M$65M$57M$50M$46M$50M
Net income-$20M-$1M-$8M$1M$3M$5M$6M$5M
Free cash flow-$4M$304105$132450$11M-$1M$5M-$1M$3M
EPS (diluted)$-1.49$-0.11$-0.58$0.08$0.24$0.38$0.44$0.39
Net margin-52.6%-5.8%-16.7%1.7%5.5%10.1%12.8%10.3%
ROIC-2.5%-0.9%-4.8%3.5%4.0%15.6%26.2%28.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is BGM Group stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does BGM Group pay a dividend?

Not currently.

Is BGM Group a good stock to buy?

We do not give buy or sell advice. BGM Group scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.